All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the International Myeloma Foundation or HealthTree for Multiple Myeloma.

  TRANSLATE

The Multiple Myeloma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Multiple Myeloma Hub cannot guarantee the accuracy of translated content. The Multiple Myeloma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

The Multiple Myeloma Hub
Brought to you by Scientific Education Support

The Multiple Myeloma Hub is an independent medical education platform, sponsored by AbbVie, Roche, Bristol Myers Squibb, Pfizer, GSK, Johnson & Johnson, Legend Biotech and Caribou Biosciences. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

View all

Now you can support HCPs in making informed decisions for their patients

Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.

Find out more

IMS Workshop 2023

Share:

Mar 24, 2023

X post image

19 May 2023

During the @Myeloma_society #IMSW23, Sarah Hammond gave a presentation on infection incidence associated with #CART and #bispecific antibody therapies.

Read our article to find out more 👉 https://t.co/BWu5H951Uo

#multiplemyeloma #MMsm #myeloma

View on 

X post image

5 May 2023

#IMSW23 | What are the resistance mechanisms to CAR T-cell therapy? Can a better understanding of them improve treatment outcomes?

Find out here 👉 https://t.co/eQhFzaxn2X

#mmsm #myeloma

View on 

X post image

25 Mar 2023

#IMSW23 Infections with #bispecifics #mmsm

View on 

X post image

25 Mar 2023

Wrapping up the #IMSW23 workshop with a great discussion on infections based on Sarah Hammond's presentation. More available data with #CARTs than #bispecifics, but additional studies are needed for optimal prevention, monitoring, and treatment #mmsm

View on 

X post image

25 Mar 2023

#IMSW23 | @apwiita reviews how targets have been identified for #myeloma and promising new ones being studied. Of note, the adequate drug class may be chosen based on antigen density and expression on non-myeloma cells #mmsm

View on 

X post image

25 Mar 2023

#IMSW23 #mmsm https://t.co/U3h7oA4UWb

View on 

X post image

25 Mar 2023

#IMSW23 | An overview of resistance mechanisms to #CARTcells in #myeloma by Niels van de Donk #mmsm

View on 

X post image

24 Mar 2023

Ending a very successful first day at #IMSW23 with @BSantomasso reviewing neurotoxicity with #CARTcells #mmsm

👉Check her recent publication, 'How I treat...' https://t.co/GVwyfGwiRv

View on 

X post image

24 Mar 2023

#IMSW23 | @SandyWong02111 highlights the awaited publication by the @ASTCT on immune effector cell associated HLH-like syndrome definition and potential treatment approaches
#CARTcells #mmsm #lymsm #leusm

https://t.co/ki01EKFLfF

View on 

X post image

24 Mar 2023

#IMSW23 | The role of toci and steroids in ameliorating toxicities experienced by patients treated with bispecifics and CARTs by @SandyWong02111 #mmsm

View on 

X post image

24 Mar 2023

#IMSW23 | Evangelos Terpos reviews response to #COVID19 vaccines in patients with #myeloma and in those treated with BCMA-directed therapies #mmsm

View on 

X post image

24 Mar 2023

#IMSW23 | @BrunoPaiva_UNAV reviews the data on MRD with #CARTcells and #bispecifics, demonstrating how its prognostic value remains with these novel therapies, although there are some key considerations when monitoring MRD after CAR T cell infusion #mmsm

View on 

X post image

24 Mar 2023

#IMSW23 | Alfred Garfall of @PennMedicine discusses the recently published results and further insights on maintenance therapy after #CARTcells
#MMSM

https://t.co/46lDuSpGtT

View on 

X post image

24 Mar 2023

#IMSW23 | Samir Parekh shares retrospective data on treating #myeloma relapsing after a #bispecific or #CARTcell and how to best sequence both strategies #mmsm

View on 

X post image

24 Mar 2023

#IMSW23 #mmsm #bispecifics @H_Einsele

View on 

X post image

24 Mar 2023

#IMSW23 | @CohenAd_MMdoc and @H_Einsele kick off the next discussion block reviewing the data on BCMA-directed bispecific antibodies #mmsm

View on 

X post image

24 Mar 2023

Great panel discussion on the current challenges with #CARTcells in #myeloma at the #IMSW23. Achieving and maintaining MRD neg, moving to earlier lines, treating patients with renal impairment... #mmsm

View on 

X post image

24 Mar 2023

#IMSW23 | Doris Hansen compares the KarMMa trial results vs. RW multicenter experience with ide-cel #CARTcells @MoffittNews #mmsm

View on 

X post image

24 Mar 2023

#IMSW23 | @NoopurRajeMD starts the day reviewing the data of the approved #CARTcells in late lines of therapy #mmsm

View on 

X post image

23 Mar 2023

The Multiple Myeloma Hub will be covering the 4th Immune Effector Cell Therapies in Multiple Myeloma Workshop.

Keep an eye on our Twitter page for key insights and interview coverage!

#IMSW23 #cancerawareness #mmsm

View on 

X post image

20 Mar 2023

The Multiple Myeloma Hub will be covering the 4th Immune Effector Cell Therapies in Multiple Myeloma Workshop.

Date: March 24–25
Location: Boston and virtual

Keep an eye on our socials for live coverage! 🗣💻

#IMSW23 #mmsm

View on 

<span>&nbsp;</span>

Please indicate your level of agreement with the following statements:

The content was clear and easy to understand

The content addressed the learning objectives

The content was relevant to my practice

I will change my clinical practice as a result of this content

More about...

IMS Workshop 2023International Myeloma Society

Your opinion matters

Regarding bispecific antibodies for multiple myeloma, which of the following do you consider the biggest hurdle for patients and caregivers?

Newsletter

Subscribe to get the best content delivered to your inbox